secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001628280-24-033743
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Q2 2024 revenue $50.5M (+10% YoY); net loss $4.5M; Fanapt bipolar launch underway
--------------------------------------------------------------------------------

- Q2 2024 total revenues $50.5M (up 10% YoY); net loss $4.5M vs net income $1.5M in Q2 2023.
- Fanapt approved for bipolar I disorder; commercial launch initiated in Q3 2024; PONVORY launch for MS also started.
- Tradipitant NDA for gastroparesis under FDA review; PDUFA date Sept 18, 2024; FDA preliminary notice of deficiencies.
- HETLIOZ net sales $18.7M (-15% YoY) amid generic competition; lawsuit vs Teva/Apotex allowed to proceed.
- Full-year 2024 guidance: total revenues $180-210M; year-end cash $360-390M; cash $387.7M at June 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828024033743/0001628280-24-033743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828024033743/vnda-20240731.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-033743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer